Role of soluble triggering receptor expressed on myeloid cells in inflammatory bowel disease

Table 1 Demographic data of IBD patients

Demographic data	Control group	Crohn’s disease	Ulcerativecolitis
Gender (Male/Female)	12/7	3/5	18/13
Age (mean ± SD, yr)	64.2 ± 14.8	29.4 ± 13.0	43.8 ± 16.4
White blood cells (mean ± SD, x 109/μL)	7.9 ± 2.3	9.0 ± 3.0a	9.5 ± 3.6a
Platelets count (mean ± SD, x 109/μL)	237 ± 56	187 ± 38a	179 ± 33a
Blood cultures	sterile	sterile	sterile
Clinical activity index of UC (mean ± SD)	-	-	1.52 ± 0.26
Endoscopic activity index of UC (mean ± SD)	-	-	1.65 ± 0.45
Crohn’s disease activity index (mean ± SD)	-	331.81±117.25	-
TNFα (median ± SE, ng/L)	6.0 ± 3.9	8.0 ± 5.1	8.4 ± 4.2a
sTREM-1 (median ± SE, ng/L)	53 ± 33	735 ± 197b	435 ± 279a
MDA (median ± SE, μmol/L)	0.93 ± 0.23	1.46 ± 0.56	1.49 ± 0.61a

^aP < 0.05,

^bP < 0.01 vs controls.

Table 2 sTREM-1, TNFα and MDA in IBD patients

Activity index	TNFα(ng/L)	sTREM-1(ng/L)	MDA(μmol/L)
UC Clinical AI
Grade 0	4.19 ± 1.52	7.09 ± 4.90	1.74 ± 0.11
1	5.13 ± 0.98	18.91 ± 15.00	1.87 ± 1.05
2	4.98 ± 0.42	288.28 ± 133.82b	1.83 ± 0.46
3	9.98 ± 1.23a	1596.45 ± 397.38b	1.97 ± 0.31
UC endoscopic AI
Grade 0	4.33 ± 1.51	4.91 ± 3.21	1.36 ± 0.11
1	5.13 ± 0.98	18.91 ± 15.00	1.87 ± 1.05
2	4.86 ± 0.41	288.28 ± 133.82b	1.66 ± 0.43
3	8.98 ± 0.42a	1108.19 ± 309.95b	1.74 ± 0.39
4	21.99 ± 10.50a	2281.25 ± 556.77b	1.91 ± 0.50
CDAI
Score < 150	4.88 ± 1.44	4.91 ± 3.21	1.78 ± 0.11
150-400	5.21 ± 0.88	16.03 ± 4.19	1.88 ± 0.67
400-600	5.67 ± 0.91	2281.25 ± 556.77a	1.95 ± 0.95

^aP < 0.05,

^bP < 0.01 vs grade 0 and score < 150.